Imugene Limited announced the appointment of Dr. Giovanni Selvaggi as Chief Medical Officer (CMO). Dr. Selvaggi is a pulmonologist, trained in thoracic malignancies management with a focus on lung cancers and mesothelioma. He brings more than a decade of experience in the pharmaceutical industry which has seen him in clinical development focused roles of increasing responsibility with GlaxoSmithKline (GSK), Novartis Oncology and Bristol Myers Squibb.

Dr. Selvaggi held a pivotal role in Novartis successful development and approval of ceritinib (or Zykadia, targeting non-small cell lung cancer/NSCLC) and was part of the immunotherapy team at Bristol Myers Squibb that led to the approval of nivolumab (Opdivo) in third line small cell lung cancer. His most recent role with US oncology company Xcovery Holdings Inc. saw Dr Selvaggi progress from CMO to be appointed CEO and CMO early in 2021. Prior to this Dr Selvaggi also served as Vice President, Clinical Development at Oncolytics Biotech in Canada.

Additionally, he has been a well-regarded presenter at major international medical conferences as well as having authored numerous peer reviewed articles in major oncology journals. Prior to entering the pharmaceutical sector Dr Selvaggi was as an attending physician at Thoracic Oncology- San Luigi Hospital in Turin, Italy. This included being an investigator on various oncology clinical trials.

Dr. Selvaggi studied at the Medical School at the University of Torino in Italy, where he also completed his Residency in Respiratory Medicine at the Postgraduate Medical School.